Intelligence

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for… Read More

#Business & Investment #Market Reports #News

#AI / data analytics / healthtech / informatics #Computer modelling #DEL #DNA #Drug discovery #Library screening #Target identification

New trends in DNA-encoded library screening

Matthew Clark, CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL… Read More

#Exclusive Content #Trends & Analysis

Preterm infant in the neonatal unit
#Brain #Financing #Neonatal #Neurodevelopmental disorders #Paediatrics #Start-ups #Tellus Therapeutics

Neonatal therapeutics company raises $35 million

Tellus Therapeutics, a company developing treatments for newborns in the neonatal intensive care unit (NICU), announced the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund.   The capital will be used to continue preclinical work conducted through the seed… Read More

#News #Start-up Zone

Protein
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #BioInnovation Institute #Biologics / Biotechnology #Investment #Proteins #Start-ups

Therapeutic protein project joins Bio Studio programme

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. The project is based on recent breakthroughs in artificial intelligence (AI) and protein design, and uses methods pioneered by David Baker’s laboratory at the University of… Read More

#News #Start-up Zone

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity… Read More

#Exclusive Content #Trends & Analysis

Human antibodies
#Antibodies #Immunotherapy #Investment #Start-ups

Start-up focusses on human-derived antibody drugs

Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. “The industry has proven the value of antibody-based… Read More

#News #Start-up Zone

Myeloma
#Cancer research #Clinical trials #Diagnostics #Market reporting #Report

Report: inequalities in access to myeloma clinical trials in Europe 

Myeloma Patients Europe (MPE) has launched an advocacy report on addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE).   The report, led by the MPE CEE Workgroup on Access, found huge inequalities for patients, confirming reports from MPE CEE members about a lack… Read More

#Cancer Research #Market Reports #News

Pedro Correa de Sampaio and Annelise Soulier
#Cancer immunotherapy #Cancer research #Financing #Start-ups

Start-up raises £520K to improve immunotherapy outcomes

Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours.  While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not… Read More

#News #Start-up Zone

EU flag
#Advanced Therapy Medicinal Products (ATMPs) #Alliance for Regenerative Medicine #Cell and gene therapy #EFPIA #EU #European Commission #European Federation of Pharmaceutical Industries and Associations #Market reporting

Can Europe become a major player in cell and gene therapy?

With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. … Read More

#Exclusive Content #Market Reports

#App note #Genetic profiling #Human disease models #Huntington's disease #Phenotyping

Characterising the phenotype of an isogenic, human iPSC-derived Huntington’s disease model by MEA

Currently, no effective cure or treatment for Huntington’s disease exists. To accelerate Huntington’s disease research and drug discovery, researchers need access to physiologically relevant human disease models that recapitulate patient phenotypes, in combination with more advanced methods to understand the underlying mechanisms of the disease. In this App Note you… Read More

#App Notes #Intelligence #Resources

#Biotechnology #Disease networks #Drug targets #Financing #Investment #Precision medicine #Start-ups

New biotech aspires to reveal insights into disease biology

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative… Read More

#News #Start-up Zone

#Biotechnology #Drug development #Drug discovery #Genomics #Synthetic biology #Synthetic DNA

Synthetic biology: Shaping the future of drug discovery 

By Lu Rahman  There are some exciting developments happening in synthetic biology and as a result the sector is highly attractive from an investment perspective. Using synthetic DNA to develop drugs and to better understand the toxic effects of them is a key driver for this market. BCC Research… Read More

#Exclusive Content #Trends & Analysis

#CAR-T #Drug development #Immuno-oncology

Advancements driving drug discovery in immuno-oncology

This latest 28 page eBook sponsored by Twist Bioscience features insights and expert opinions on the latest advancements occurring in immuno-oncology and drug discovery. Read this eBook to learn about: The challenges and opportunities facing CAR-T cell therapies Targeting GPCRs in cancer drug discovery The immuno-oncology landscape and its many… Read More

#DDW eBooks #Intelligence

Genomics
#Biotechnology #Comment #Data #Gene editing #Genetics / genomics #Genome sequencing #Healthcare #Public health #Research #Whole genome sequencing

Why genomic healthcare data matters in the development of new therapies 

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact.  The origins  One might… Read More

#Exclusive Content #Opinion #Trends & Analysis

Eurofins Guide
#Drug development #Drug discovery #Guide #Hit to lead #Hit-finding #Lead optimisation

Hit-finding strategies for potent and specific molecules

Download the guide for hit-finding tools that will accelerate your hit to lead and lead optimisation programs for CNS, metabolic, oncology and other therapeutic areas. Synthetic, medicinal, and computational chemistry capabilities along with in house available diversity and focused libraries Small molecule and biologics targeted screening for GPCRs, kinases, ion… Read More

#Resources